MX384875B - Método para obtener una vacuna de mycoplasma. - Google Patents

Método para obtener una vacuna de mycoplasma.

Info

Publication number
MX384875B
MX384875B MX2018014818A MX2018014818A MX384875B MX 384875 B MX384875 B MX 384875B MX 2018014818 A MX2018014818 A MX 2018014818A MX 2018014818 A MX2018014818 A MX 2018014818A MX 384875 B MX384875 B MX 384875B
Authority
MX
Mexico
Prior art keywords
obtaining
subject
immunogenic composition
mycoplasma
relates
Prior art date
Application number
MX2018014818A
Other languages
English (en)
Inventor
Arun V Iyer
Axel Neubauer
Brian Thomas Martinson
Christine Margaret Muehlenthaler
Dianna M Murphy Jordan
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX384875(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of MX384875B publication Critical patent/MX384875B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

La presente invención se refiere, entre otros, a un método para la preparación de una composición inmunogénica para el tratamiento y/o la profilaxis de infecciones por micoplasmas en un sujeto, que comprende cultivar bacterias de Mycoplasma en un sistema de células eucarióticas con una cantidad reducida de suero o libre de suero porcino; obtener un antígeno de las bacterias de Mycoplasma; y agregar un portador farmacéuticamente aceptable. Además, la presente invención se refiere a la composición inmunogénica que se puede obtener mediante dicho método y a un método para inmunizar a un sujeto, que comprende la administración de la composición inmunogénica a un sujeto.
MX2018014818A 2012-12-28 2013-12-20 Método para obtener una vacuna de mycoplasma. MX384875B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261746997P 2012-12-28 2012-12-28
PCT/US2013/076807 WO2014105672A1 (en) 2012-12-28 2013-12-20 Method of making a mycoplasma vaccine

Publications (1)

Publication Number Publication Date
MX384875B true MX384875B (es) 2025-03-14

Family

ID=49917778

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015007730A MX361273B (es) 2012-12-28 2013-12-20 Metodo para obtener una vacuna de mycoplasma.
MX2018014818A MX384875B (es) 2012-12-28 2013-12-20 Método para obtener una vacuna de mycoplasma.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015007730A MX361273B (es) 2012-12-28 2013-12-20 Metodo para obtener una vacuna de mycoplasma.

Country Status (23)

Country Link
US (2) US9273281B2 (es)
EP (1) EP2938747B1 (es)
JP (2) JP6122146B2 (es)
KR (1) KR102153275B1 (es)
CN (2) CN104968365B (es)
AR (1) AR094648A1 (es)
AU (1) AU2013370983B2 (es)
BR (1) BR112015012711B1 (es)
CA (1) CA2896298C (es)
CL (1) CL2015001562A1 (es)
DK (1) DK2938747T3 (es)
EA (1) EA032772B1 (es)
ES (1) ES2738100T3 (es)
HU (1) HUE045015T2 (es)
MX (2) MX361273B (es)
MY (1) MY173223A (es)
PH (1) PH12015501333B1 (es)
PL (1) PL2938747T3 (es)
PT (1) PT2938747T (es)
SG (2) SG11201505089YA (es)
TW (2) TWI618542B (es)
UA (1) UA121193C2 (es)
WO (1) WO2014105672A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
KR102355614B1 (ko) * 2012-12-28 2022-01-27 베링거잉겔하임베트메디카게엠베하 마이코플라스마 항원을 포함하는 면역원성 조성물
PT2938747T (pt) * 2012-12-28 2019-08-01 Boehringer Ingelheim Vetmedica Gmbh Método de preparação de uma vacina de micoplasma
CN105441368B (zh) * 2016-01-19 2019-01-01 福清市默克兽医院 一株牛支原体及其应用
US10222383B2 (en) 2016-01-29 2019-03-05 Advanced Animal Diagnostics, Inc. Methods and compositions for detecting mycoplasma exposure
WO2017165570A1 (en) 2016-03-22 2017-09-28 Advanced Animal Diagnostics, Inc. Methods and compositions for reducing antibiotic administration to farm animals
EP3498728A4 (en) * 2016-08-09 2020-03-25 Agricultural Technology Research Institute COMPOSITION FOR THE PREVENTION AND TREATMENT OF A LEMYCOPLASMA HYORHINIS INFECTION
US20180221407A1 (en) * 2017-02-03 2018-08-09 The Administrators Of The Tulane Educational Fund Ophthalmic compositions for therapeutic and prophylactic uses
EP3632982A4 (en) 2017-05-24 2020-04-08 Mitsubishi Chemical Corporation MOLDING MATERIAL, AND FIBER REINFORCED COMPOSITE MATERIAL
CN114375326A (zh) 2019-06-10 2022-04-19 礼蓝美国公司 支原体培养基制剂
CN113201050B (zh) * 2020-08-06 2022-07-22 青岛诺安百特生物技术有限公司 一种金黄色葡萄球菌噬菌体穿孔素及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
GB1074920A (en) * 1965-04-21 1967-07-05 Pfizer & Co C Growth medium for mycoplasma pneumoniae and vaccine production
GB1137306A (en) * 1966-07-11 1968-12-18 Research Corp Inoculum for poultry
JPS5540568B2 (es) 1972-10-05 1980-10-18
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5885823A (en) 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
AU2001236042B9 (en) 2000-03-03 2006-06-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
JP3402304B2 (ja) * 2000-03-30 2003-05-06 株式会社微生物化学研究所 猫クラミジアワクチンの製造方法
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
EP2842569B1 (en) 2001-07-02 2019-04-10 Zoetis Services LLC One dose vaccination with Mycoplasma hyopneumoniae
BR0211049A (pt) 2001-07-02 2004-07-20 Pfizer Prod Inc Método de tratamento ou prevenção de doenças ou disfunções e uso de mycoplasma hyopneumoniae
US20030147914A1 (en) 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
WO2003017755A2 (en) 2001-08-28 2003-03-06 Pfizer Products Inc. Mycoplasma bovis challenge model, methods for administering m.bovis and methods for inducing pneumonic lung lesions
TWI238721B (en) * 2003-06-20 2005-09-01 Animal Technology Inst Taiwan Swine enzootic vaccine, its producing method and usage
JP2008529827A (ja) 2005-02-09 2008-08-07 マグナ インターナショナル インコーポレイテッド 半構造的パネルの製造方法
JP4693839B2 (ja) * 2005-03-10 2011-06-01 共立製薬株式会社 動物由来の成分なしで培養可能である細胞株及びその作出方法、これを用いたウイルスの生産方法、及びワクチンの生産方法
EP1934598B1 (en) * 2005-10-14 2010-09-22 Ivan Mikhailovich Petyaev Diagnosis of obligate intracellular pathogens
CN101627113B (zh) 2006-09-15 2013-04-24 米迪缪尼有限公司 支持病毒生长到高效价的mdck细胞系和采用该细胞系的生物反应器方法
US20090068231A1 (en) 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
UY31437A1 (es) 2007-10-29 2009-05-29 Vacuna de mycoplasma bovis y métodos de uso de la misma
WO2009061798A1 (en) * 2007-11-06 2009-05-14 Wyeth Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine
KR20100113582A (ko) 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
JPWO2009142086A1 (ja) 2008-05-23 2011-09-29 学校法人 久留米大学 マイコプラズマ感染症用ワクチン組成物
NZ709547A (en) 2008-06-27 2017-01-27 Zoetis Services Llc Novel adjuvant compositions
AU2009309041B2 (en) 2008-10-31 2016-02-04 Boehringer Ingelheim Animal Health USA Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
WO2010132932A1 (en) 2009-05-19 2010-11-25 Bioproperties Pty Ltd A temperature sensitive vaccine strain of mycoplasma hyopneumoniae and uses thereof
US20110150770A1 (en) 2009-12-18 2011-06-23 Boehringer Ingelheim Vetmedica, Inc. Multivalent vaccine against porcine teschovirus and other disease causing organisms in swine
US8112663B2 (en) 2010-03-26 2012-02-07 Lsi Corporation Method to establish redundancy and fault tolerance better than RAID level 6 without using parity
CN102258776B (zh) 2011-07-07 2013-07-10 普莱柯生物工程股份有限公司 猪肺炎支原体、猪鼻支原体二联灭活疫苗及其制备方法
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
KR102355614B1 (ko) * 2012-12-28 2022-01-27 베링거잉겔하임베트메디카게엠베하 마이코플라스마 항원을 포함하는 면역원성 조성물
PT2938747T (pt) * 2012-12-28 2019-08-01 Boehringer Ingelheim Vetmedica Gmbh Método de preparação de uma vacina de micoplasma

Also Published As

Publication number Publication date
US9273281B2 (en) 2016-03-01
EP2938747B1 (en) 2019-05-01
MY173223A (en) 2020-01-07
ES2738100T3 (es) 2020-01-20
AU2013370983A1 (en) 2015-05-21
US20160136254A1 (en) 2016-05-19
MX361273B (es) 2018-12-03
EP2938747A1 (en) 2015-11-04
BR112015012711B1 (pt) 2022-08-16
PT2938747T (pt) 2019-08-01
JP6122146B2 (ja) 2017-04-26
JP6449364B2 (ja) 2019-01-09
TW201438732A (zh) 2014-10-16
PH12015501333B1 (en) 2022-10-05
JP2017145253A (ja) 2017-08-24
TWI618542B (zh) 2018-03-21
CA2896298C (en) 2024-01-16
AU2013370983B2 (en) 2019-09-26
WO2014105672A1 (en) 2014-07-03
BR112015012711A2 (pt) 2017-07-11
US20140186394A1 (en) 2014-07-03
EA032772B1 (ru) 2019-07-31
SG11201505089YA (en) 2015-07-30
TWI660736B (zh) 2019-06-01
MX2015007730A (es) 2015-09-07
PH12015501333A1 (en) 2015-09-02
JP2016508983A (ja) 2016-03-24
HUE045015T2 (hu) 2019-11-28
CN108379571A (zh) 2018-08-10
KR102153275B1 (ko) 2020-09-09
TW201832777A (zh) 2018-09-16
KR20150100920A (ko) 2015-09-02
CA2896298A1 (en) 2014-07-03
EA201500701A1 (ru) 2015-12-30
CN104968365B (zh) 2018-04-03
UA121193C2 (uk) 2020-04-27
CL2015001562A1 (es) 2016-06-24
PL2938747T3 (pl) 2019-11-29
AR094648A1 (es) 2015-08-19
DK2938747T3 (da) 2019-08-05
SG10201708028VA (en) 2017-10-30
US10512680B2 (en) 2019-12-24
CN104968365A (zh) 2015-10-07

Similar Documents

Publication Publication Date Title
MX384875B (es) Método para obtener una vacuna de mycoplasma.
CY1116835T1 (el) Νεο ευρωπαϊκο στελεχος toy prrsv
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA201792407A3 (ru) Композиции, содержащие буфер, составы вакцин, которые содержат композиции, содержащие буфер, и пути их применения
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
IN2013MU00711A (es)
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
MX382924B (es) Composición para prevenir infección por mycoplasma spp.
EP4321218A3 (en) Cancer stem cell targeted cancer vaccines
EA201491845A1 (ru) Получение стерильных активных фармацевтических ингредиентов
PH12015501335A1 (en) Immunogenic composition comprising mycoplasma antigens
MX363044B (es) Vacuna de virus de schmallenberg (sbv), metodos de produccion y sus usos.
MX385188B (es) Vacuna de rinitis equina.
IN2013CH04314A (es)
CO2018001531A2 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
AR093687A2 (es) Vacunas
IN2013MU01944A (es)